These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26805700)

  • 1. MKK3 as oncotarget.
    Bossi G
    Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.
    Baldari S; Ubertini V; Garufi A; D'Orazi G; Bossi G
    Cell Death Dis; 2015 Jan; 6(1):e1621. PubMed ID: 25633290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
    Italiano A
    Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
    Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
    Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
    Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
    Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer.
    Stramucci L; Bossi G
    J Exp Clin Cancer Res; 2019 Dec; 38(1):504. PubMed ID: 31881903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
    Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
    Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.
    Alain T; Sonenberg N; Topisirovic I
    Oncotarget; 2012 Dec; 3(12):1491-2. PubMed ID: 23455427
    [No Abstract]   [Full Text] [Related]  

  • 12. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in targeting signal transduction pathways.
    McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
    Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell division on-off switches sought as targets for cancer drugs.
    Hampton T
    JAMA; 2005 Apr; 293(15):1847. PubMed ID: 15840846
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapies for anaplastic thyroid cancer.
    Agrawal VR; Hreno J; Patil T; Bowles DW
    Drugs Today (Barc); 2018 Nov; 54(11):695-704. PubMed ID: 30539168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 19. The Evolving Landscape of HER2 Targeting in Breast Cancer.
    Moasser MM; Krop IE
    JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.